SCHEMBL2080480

SCHEMBL2080480

N#Cc1c(F)ccc(C(=O)O)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
TAS1R2 Q8TE23 1/20 0.40
NOTUM Q6P988 2/20 0.40
KDM4E B2RXH2 1/20 0.39
ASPH Q12797 1/20 0.39
KDM8 Q8N371 1/20 0.39
MAP2K1 Q02750 2/20 0.38
CYP1A2 P05177 1/20 0.38
ALB P02768 1/20 0.37
MAP2K2 P36507 1/20 0.36
XDH P47989 1/20 0.35
SLC22A12 Q96S37 1/20 0.35
TSHR P16473 1/20 0.34
CASP1 P29466 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GRIA2 P42262 1/20 0.34
GRIA4 P48058 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18149189 0.81 NOTUM (0.43) TAS1R3TAS1R1TAS1R2NOTUMKDM4E
SCHEMBL28363838 0.79 CYP1A2 (0.52) NOTUMKDM4ECYP1A2XDHSLC22A12
SCHEMBL30798293 0.78 NOTUM (0.37) TAS1R3TAS1R1TAS1R2NOTUMKDM4E
SCHEMBL24717809 0.78 NOTUM (0.37) TAS1R3TAS1R1TAS1R2NOTUMKDM4E
SCHEMBL5110105 0.78 MAPT (0.46) NOTUMKDM4ESLC22A12
SCHEMBL5026544 0.78 FOLH1 (0.43) KDM4EXDHSLC22A12TSHRSMN1; SMN2
SCHEMBL3552234 0.77 KEAP1 (0.39) CES2CES1NOTUMKDM4EASPH
SCHEMBL30961765 0.77 ALB (0.55) CES2CES1TAS1R3TAS1R1TAS1R2
SCHEMBL28331532 0.77 ALB (0.55) CES2CES1TAS1R3TAS1R1TAS1R2
SCHEMBL241797 0.74 CES2 (0.70) CES2CES1KDM4EASPHKDM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902226-B2 Dehalogeno-compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
EP-1336611-B1 DEHALOGENO COMPOUNDS DAIICHI SEIYAKU CO (JP) 2007-09-05 EP disclosed
US-20070123560-A1 Dehalogeno-compounds DAIICHI PHARMACEUTICAL CO., LTD. 2007-05-31 US disclosed
US-20040063754-A1 Dehalogeno compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1336611-A1 DEHALOGENO COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063754-A1 Dehalogeno compounds DEK, PGLS, RPS27L CES2 762/4885CES1 956/4885TAS1R3 1943/4885
US-20070123560-A1 Dehalogeno-compounds DEK, RPS27L, POLL CES2 1028/4885CES1 1176/4885TAS1R3 1840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.